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Background: Cystic fibrosis (CF) is considered to be very rare in Indian subcontinent. Based on reports of CF in migrants from Indian
subcontinent to United Kingdom and United States of America, the prevalence of CF is estimated to be between 1 /10,000 and 1 /40,000 in
this ethnic group. The present study was done to estimate the carrier frequency of F508del mutation among neonates using cord blood
samples to reflect the prevalence of CF in the study population.
Methods: 955 mothers delivering at our hospital between December 1999 and November 2000 were enrolled. Cord blood samples were
analyzed for F508del mutation using polymerase chain reaction and gel electrophoresis. The frequency of patients homozygous for F508del
mutation in the population was estimated using Hardy–Weinberg principle. The prevalence of CF was estimated by using the proportion of
F508del homozygous cases out of all CF patients, as reported in various studies (19–44%) from Indian subcontinent.
Results: Out of 955 cord blood samples, 4 were positive for F508del mutation. The carrier frequency and gene frequency of F508del
mutation in the Indian population was calculated to be 1 /238 (0.42%) and 1 /477 (0.21%), respectively. Frequency of CF patients
homozygous for F508del mutation is 1 /228,006. The estimated prevalence of CF is 1 /43,321 to 1 /100,323 in Indian population.
Conclusion: CF does occur in Indian subcontinent though the prevalence is lesser than the Caucasian population.
D 2005 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; F508del; Carrier frequency
1. Introduction cystic fibrosis transmembrane conductance regulatorCystic fibrosis (CF) is a multi-system disease involving
various epithelial cells of the body due to mutations in the1569-1993/$ - see front matter D 2005 European Cystic Fibrosis Society. Publish
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disorder in the Caucasian population with an average
frequency of 1 /2000 though the prevalence varies with the
geographical location [1–6]. The prevalence of CF ranges
from 1/620 in a confined population of Dutch descent in
South-West Africa to 1 / 5600 in Sweden [7,8]. The
frequency of F508del mutation in Caucasian CF population
has been reported to be approximately 70% [9]. More than
1000 other mutations have been reported so far in the CFTR
gene (www.genet.sickkids.on.ca/cftr-cgi-bin/Full Table).
There are only a few reports of cystic fibrosis affecting
people of Asian origin. The suggested incidence of CF in
the Asian migrants in the United Kingdom is about 1 /s 5 (2006) 43 – 46ed by Elsevier B.V. All rights reserved.
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proportion of CF disease due to homozygous F508del status
varies from 19% to 44% [11–13]. CF patients with
homozygous F508del mutation suffer from severe disease
causing early death which may lead to underestimation of
the prevalence of F508del mutation. Therefore, a higher
prevalence of F508del mutation is expected in neonatal
surveys. Objective of the present study was to estimate the
carrier frequency of F508del mutation among neonates
using cord blood samples to reflect the prevalence of CF in
the study population.2. Patients and methods
The present study was conducted at the Neonatal and
Genetics Division of Department of Pediatrics, All India
Institute of Medical Sciences, New Delhi.
2.1. Sample size
Presuming the frequency of CF carriers in our
population to be same as in the Caucasian population
i.e., 1 /25 (4%), with percentage of F508del being 70% of
all mutations in CF disease and taking allowable error Fr_
as 40%, the required sample size would be 867. On the
other hand, if we presume the frequency of CF to be
around 1 /10,000 according to the study by Goodchild et
al. [10] and taking allowable error Fr_ as 20%, the required
sample size would be 7042. As we did not have any
reliable background data on either the CF prevalence or
the frequency of F508del mutation in Indian population,
we planned a feasible pilot study with a sample size of
1000 cord blood samples.
Women delivering in our hospital from December 1999
to November 2000 were enrolled in the present study. Data
regarding the place of origin of parents, obstetric and
neonatal complications and history suggestive of CF in the
family were recorded in a pre-designed proforma. After
obtaining prior informed consent from the parents, 5 ml cord
blood sample was collected in EDTA vacutainers at the time
of delivery taking all sterile precautions. The samples were
stored at 4 -C and processed weekly. DNA was extracted
from the blood samples using either phenol–chloroform or
salt extraction method [14]. The extracted DNA was
subjected to polymerase chain reaction (PCR) using specific
primer sequences. PCR conditions were as described by
Chris Mathews et al. [15]. The PCR products were run on an
8% polyacrylamide gel and silver stained. The normal
product size of this PCR is 50 base pairs and deletion of 3
base pairs in the exon 10 at codon 508 gives a product size
of 47 base pairs. If a carrier of F508del was detected then
the concerned family was contacted and a sweat chloride
test was performed to rule out CF disease in the child.
Hardy–Weinberg principle was used to estimate the
frequency of F508del homozygous disease [16].3. Results
Around 2000 deliveries were conducted at All India
Institute of Medical Sciences from November 1999 to
October 2000, out of which 1019 cord blood samples were
collected. Data regarding the place of origin of parents was
available in 960 cases. In 64 samples out of 1019 samples,
results could not be obtained either due to failure of DNA
extraction, failure of PCR or gel electrophoresis despite
repeating the procedure. Out of the 1019 cord blood
samples, results were thus available for 955 cord blood
samples.
As Delhi is a cosmopolitan city, our study population
had people with origins from all over the country.
Maximum number of people (¨45%) in the study had
origin from Delhi i.e., 441 /960 mothers and 436 /960
fathers. This was followed by people with origin from
other Northern Indian states of Uttar Pradesh, Haryana,
Bihar and Punjab. Approximately 5% originated from
Pakistan and 3.5% parents had origin from Kerala. History
of consanguinity was present in 2 families and in one of
these the cord blood sample was positive for F508del
mutation.
History of recurrent pneumonia in previous babies was
present in 11 families, recurrent diarrhea in 3 families, sib
death in 6 families and doubtful history of meconium ileus
was present in 2 families. None of the families had a history
of confirmed CF in the family. None of the patients detected
as carriers of F508del had any family members with a
history suggestive of CF.
Many women had medical and obstetric complication
unrelated to CF. However, none of the mothers in those
cases, where cord blood sample was positive for F508del
mutation, had any significant medical or obstetric compli-
cations. Unrelated ultrasound abnormalities were detected in
11 instances. Echogenic bowel or meconium peritonitis was
not detected on antenatal ultrasound examination in any
patient.
In our study, out of the 955 cord blood samples four were
positive for F508del mutation. These four positive samples
could have been either carriers for F508del mutation or
compound heterozygotes for F508del with some other
mutation and not true homozygotes. Out of the four
concerned families, three could be contacted for follow
up. All the three children are healthy till date with normal
sweat chloride values, confirming their carrier status.
Therefore, the carrier frequency of F508del mutation in
our study population is 4 /955=1 /238 (0.42%). The gene
frequency of F508del mutation is 4 / 9552=1 / 477
(0.21%). Therefore, the frequency of homozygous F508del
disease is estimated to be 1 /228,006 (Table 1). In various
CF studies in Asian populations, the prevalence of F508del
homozygotes among all CF patients ranges from ~19% to
44% [11–13]. Using this data, the estimate of total CF cases
in our study population would range from 1/43,321 to 1 /
100,323.
Table 1
Carrier frequency of F508del mutation and estimation of CF prevalence in
Indian population
Carrier frequency of F508del
mutation (i.e.2q) (No. of cord
blood samples with F508del mutation)
4 /955 or 1 /238 (0.42%)
(1 /232 to 1 /245; 95%
confidence intervals)
SD=0.002, SE=0.002/
955=6.4105
CF disease due to F508del homozygous
cases (=q2 By Hardy–Weinberg
principle )
1 out of 228,006 study
population (0.004 /1000)
Estimated total CF prevalence due to
all mutations
*1 /43, 321 to 1 /100,323
* Considering homozygous F508del cases to range from 19% to 44% of
all CF cases respectively in different studies [11–13].
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different places of origin i.e., Pakistan, Karnataka, Jammu
and Uttar Pradesh.4. Discussion
Our study was designed to estimate the magnitude of CF
in an Asian population by finding the prevalence of the most
common mutation i.e., F508del. There are no large studies
on prevalence of CF in Asian population.
In our study, out of the 955 cord blood samples that
could be analyzed completely, 4 samples were positive for
F508del mutation, giving F508del carrier frequency as 1 /
238 or 0.42% and estimated CF prevalence as 1 /43,321 to
1 /100,323. Our estimated prevalence of CF disease is lesser
than the prevalence reported in the migrant Asian studies
from UK (around 1 /10,000 by Goodchild et al) [10]. This
seems to be in concordance with the view that cystic fibrosis
is rare amongst Asians.
The ethnic background characteristics of the study
population could have contributed to the low prevalence
of CF in the present study. Only 8.8% of our study
population (5.3% from Pakistan and 3% from Punjab) had
ethnic background from regions which are considered to
have higher prevalence of F508del mutation [17]. Although
this aspect might not affect the estimation of CF prevalence
in entire Indian population, because of probably a similar
distribution of such ethnic groups when averaged over the
whole country.
The desirable sample size to determine the prevalence of
CF in the Indian population considering the study in Asian
migrants to UK [10] would be around 7000. The previous
studies were small and could also be suffering from an
ethnic bias. A larger study may be useful to confirm the
findings of present study.
Though our hospital is a tertiary care center, there is little
possibility of referral bias in our study as the obstetric or
medical complications in the patients were unrelated to CF
and none of the mothers of F508del carriers had any medical
or obstetric complications. At times, the cord blood samplescould not be collected especially when the mother or the
newborn required immediate medical attention. This could
introduce a selection bias in our study.
The population of India according to 2001 census is
approximately 1.028 billion with crude birth rate of 25 /
1000. Due to the size of Indian population, despite a low
prevalence, there could be anywhere between 10,247 to
23,730 CF patients in India, considering no deaths. Out
of 25.7 million births annually 256 to 593 children could
be suffering from CF. Similarly out of the total
population of 13.8 million in Delhi there could be 137
to 318 CF cases.
Though the present study appears to corroborate the view
that CF is less common in the Indian population, it is
important to note that due to the magnitude of Indian
population, the total disease load because of CF could be
more than many European countries.Acknowledgements
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